Antisense oligonucleotides (ASOs) are short, synthetic strands of genetic material designed to bind to specific RNA molecules inside your cells and change how a particular protein gets made. They work by pairing up with a target RNA sequence using the same base-pairing rules that hold together your DNA’s double helix. Since 1998, when the first ASO drug was approved, the field has grown to include over a dozen FDA-approved therapies for conditions ranging from spinal muscular atrophy to high cholesterol to ALS.
How ASOs Work Inside Your Cells
Unlike traditional drugs that latch onto proteins to block their activity, ASOs intervene one step earlier. They target the RNA messages your cells use as blueprints for building proteins. An ASO is designed with a sequence that perfectly complements a stretch of a specific RNA molecule, so it locks on with high precision.
Once bound, an ASO can alter protein production in two main ways. The first, and most common among approved drugs, is triggering destruction of the RNA. When the ASO attaches to its target, the paired structure is recognized by a natural enzyme called RNase H, which cuts the RNA strand apart. With the blueprint destroyed, the cell can no longer make the unwanted protein. Drugs that use this approach are often built with a “gapmer” design: a central stretch of unmodified building blocks that activates the enzyme, flanked by chemically modified ends that help the drug resist being broken down and stick more tightly to its target.
The second approach is splicing modulation. Before an RNA message is finalized, your cells edit it by cutting out certain segments and stitching the rest together. ASOs can interfere with this editing process. In some cases, they force the cell to skip over a faulty section of the message, producing a shorter but still functional protein. In other cases, they block the editing machinery from accessing certain spots, forcing the cell to include a segment it would normally remove. This doesn’t destroy the RNA. Instead, it redirects the cell to build a different, often more useful, version of the protein.
Three Generations of Chemical Design
A naked strand of synthetic genetic material wouldn’t survive long in your body. Enzymes in your blood and tissues would chew it apart within minutes. Decades of chemistry have produced three broad generations of modifications that make ASOs durable enough to work as drugs.
First-generation ASOs replaced a key chemical link in the backbone (the phosphate bond between each building block) with a sulfur-containing version called a phosphorothioate. This single change dramatically increased resistance to the enzymes that break down genetic material, extending the drug’s working life from minutes to hours. It also helped ASOs stick to blood proteins, which slows their clearance from the body and gives them time to move from the bloodstream into tissues.
Second-generation ASOs added modifications to the sugar portion of each building block. The most widely used is a modification called MOE (2′-methoxyethyl), which further boosts binding strength and stability. These changes made ASOs potent enough to be given at lower doses and less frequently. Most currently approved ASO drugs use some combination of phosphorothioate backbone chemistry and second-generation sugar modifications.
Third-generation designs include more structurally constrained modifications like locked nucleic acids, which lock the sugar into a rigid shape for even tighter RNA binding, and morpholino-based backbones, which replace the sugar-phosphate structure entirely. These newer chemistries expand the toolkit, allowing drug designers to fine-tune how strongly an ASO binds, how long it lasts, and which tissues it reaches.
Approved ASO Drugs
The first ASO to reach patients was fomivirsen (Vitravene), approved by the FDA in 1998 for a viral eye infection called CMV retinitis. It proved the concept worked, but the field took years to mature. The pace has accelerated sharply since 2016, with new approvals arriving nearly every year.
Some of the most notable approved ASO therapies include:
- Nusinersen (Spinraza), 2016: treats spinal muscular atrophy (SMA), a genetic disease that destroys motor neurons. It works by modifying how the SMN2 gene is spliced, forcing inclusion of a critical segment that produces a functional protein. Without treatment, many children with severe SMA do not survive past age two.
- Eteplirsen, golodirsen, viltolarsen, and casimersen (2016–2021): four separate ASOs approved for Duchenne muscular dystrophy (DMD), each targeting a different genetic mutation. They all use exon-skipping to restore a partially functional version of the dystrophin protein.
- Inotersen (Tegsedi), 2018: treats hereditary transthyretin amyloidosis, a condition where a misfolded protein accumulates in nerves and organs.
- Inclisiran (Leqvio), 2021: lowers cholesterol in people with familial hypercholesterolemia, given as an injection just twice a year after initial dosing.
- Tofersen (Qalsody), 2023: the first ASO approved for ALS, specifically for patients whose disease is caused by mutations in the SOD1 gene. It received accelerated approval based on its ability to reduce a blood marker of nerve damage called neurofilament light chain.
The Delivery Problem
Getting ASOs to the right tissue remains one of the biggest challenges in the field. ASOs are large, electrically charged molecules that don’t easily cross cell membranes on their own. Reaching the liver is relatively straightforward because ASOs naturally accumulate there after injection into the bloodstream. Reaching the brain and spinal cord is far harder.
The blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels, blocks most ASOs from entering the central nervous system. Nusinersen, the SMA drug, gets around this by being injected directly into the spinal fluid through a lumbar puncture, repeated every four months. This works, but it’s invasive and requires a clinical setting.
Researchers are actively developing alternatives. One promising approach conjugates ASOs to small peptides derived from proteins that naturally cross the blood-brain barrier, like fragments of apolipoprotein E (a protein involved in cholesterol transport). In mouse studies, these peptide-ASO conjugates delivered meaningful drug levels to the brain and spinal cord after a simple injection under the skin or into a vein. Versions made with specially engineered peptides showed extended stability in the bloodstream, raising hope that future CNS-targeted ASOs could be given systemically rather than through spinal injections.
Side Effects and Monitoring
ASO drugs are generally well tolerated compared to many traditional therapies, but they carry a consistent set of risks that require monitoring. Eight of the 14 FDA-approved ASO drugs carry warnings for hypersensitivity reactions, liver toxicity, or kidney toxicity. Two, mipomersen and inotersen, carry the FDA’s most serious warning label (a black box) for their potential to damage the liver and kidneys.
Kidney effects are the most common concern across the class. Five approved ASOs carry specific warnings for kidney toxicity, with findings that can include protein leaking into the urine, inflammation of the kidney’s filtering units, and, in rare cases, progression toward kidney failure. In clinical trials of nusinersen, roughly 70% of treated patients developed elevated protein levels in their urine, though kidney function measured by other markers stayed normal. Inotersen posed a more serious risk: about 3% of patients in trials developed significant kidney inflammation.
For patients on these drugs, regular urine and blood tests are standard. The specific monitoring schedule varies by drug, but typically involves checking for protein in the urine monthly and measuring kidney function markers every few months. For patients with Duchenne muscular dystrophy, standard kidney markers like creatinine can be unreliable because muscle wasting lowers creatinine levels independently, so doctors use alternative measures.
ASOs in Neurological Disease
The central nervous system has become the most active area for ASO development. Beyond the approved drugs for SMA and ALS, several programs are targeting other neurodegenerative conditions.
Huntington’s disease drew enormous attention when an ASO called tominersen entered a large clinical trial. The drug successfully lowered levels of the toxic huntingtin protein in spinal fluid. But in 2021, an independent safety board recommended halting the trial. Patients receiving the drug every eight weeks actually performed worse on clinical measures than those on placebo and experienced more serious adverse events. The result was a major setback, illustrating that reducing a disease protein doesn’t automatically translate into clinical benefit, especially when the drug also suppresses the normal version of that protein.
A newer approach for Huntington’s uses an ASO called WVE-003, designed to selectively target only the mutant copy of the huntingtin gene while leaving the normal copy intact. It entered early-stage clinical trials in 2021 and represents the only allele-selective ASO candidate currently in development for the disease. The distinction matters because the normal huntingtin protein plays important roles in brain cell health, and preserving it may avoid the problems that derailed tominersen.